0610012H03Rik Activators
0610012H03Rik Activators encompass a diversity of chemical compounds that indirectly promote the functional activity of 0610012H03Rik through distinct signaling pathways. Forskolin and IBMX, by raising intracellular cAMP levels, activate PKA, which is known to phosphorylate proteins within the cellular milieu of 0610012H03Rik, thereby enhancing its activity. P0610012H03Rik Activators encompass a diversity of chemical compounds that indirectly promote the functional activity of 0610012H03Rik through distinct signaling pathways. Forskolin and IBMX, by raising intracellular cAMP levels, activate PKA, which is known to phosphorylate proteins within the cellular milieu of 0610012H03Rik, thereby enhancing its activity. Phorbol 12-myristate 13-acetate (PMA) stimulates PKC pathways, which can lead to the activation of downstream signaling events involving 0610012H03Rik. Epigallocatechin gallate and the PI3K inhibitor LY294002 alter kinase activity and PI3K/Akt signaling, respectively, creating a favorable context for the activation of pathways in which 0610012H03Rik is a participant. This is further complemented by the actions of U0126 and PD 98059, which by inhibiting MEK, reduce MAPK/ERK pathway signaling and potentially enhance signaling routes that 0610012H03Rik is involved in.
The bioactivity of 0610012H03Rik is also modulated by compounds that influence intracellular calcium levels. A23187 (Calcimycin) and Thapsigargin both disrupt calcium homeostasis, which can activate calcium-dependent signaling mechanisms integral to 0610012H03Rik's function. Similarly, Sphingosine-1-phosphate elicits a cascade of events through its receptors, affecting MAPK and PI3K/Akt pathways that can intersect with the signaling landscape of 0610012H03Rik, enhancing its function. Lastly, SB203580's inhibition of p38 MAPK redirects cellular signaling in a manner that may favor 0610012H03Rik activation. Collectively, these activators function through a variety of mechanisms to enhance the pathways and processes that are central to the functional activity of 0610012H03Rik, without increasing its expression or direct stimulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate engages with its receptors to initiate signaling cascades that culminate in the activation of the MAPK and PI3K/Akt pathways. These pathways are known to intersect with the cellular processes that 0610012H03Rik is involved in, thereby enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which in turn can phosphorylate a variety of proteins. The PKC-mediated phosphorylation events can lead to the activation of signaling pathways that 0610012H03Rik participates in, promoting its functional activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate is known to inhibit certain kinases, which can reduce competitive signaling and enhance pathways in which 0610012H03Rik is active, thus indirectly increasing the functional activity of 0610012H03Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which alters the PI3K/Akt pathway. This modulation can favor the activation of alternative pathways, including those involving 0610012H03Rik, thereby enhancing its activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor, but its action can lead to the selective enhancement of pathways involving 0610012H03Rik by reducing the activity of inhibitory kinases that regulate 0610012H03Rik-related processes. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as an ionophore, increasing intracellular calcium levels. The elevation of calcium can activate calcium-dependent signaling pathways which are crucial for the processes that 0610012H03Rik is involved in, thus enhancing its activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX inhibits phosphodiesterases, leading to increased cAMP levels, which can activate PKA. PKA potentially enhances the signaling pathways that 0610012H03Rik is part of, resulting in increased functional activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to an increase in cytosolic calcium levels. The alteration in calcium homeostasis can enhance the activity of 0610012H03Rik through calcium-dependent signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK, which indirectly could enhance pathways that involve 0610012H03Rik by reducing ERK pathway signaling and shifting the balance towards 0610012H03Rik's activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, leading to the modulation of the p38 MAPK pathway. This inhibition can result in the activation of alternative pathways, including those associated with 0610012H03Rik, thus enhancing its activity. | ||||||